Daiichi Sankyo commences trial for booster mRNA vaccine against Covid-19

DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by the company

Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products

As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio

Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy

Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab

Daiichi Sankyo initiates Phase 2 trial of mRNA Covid-19 vaccine in Japan

It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus

Senhwa Biosciences launches groundbreaking trial for HER2-positive tumours

CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development

ENHERTU gains first-ever nod in China for metastatic breast cancer

The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy

FDA grants breakthrough therapy designation to Enhertu for high-risk early breast cancer

This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care

MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT

Merck advances cancer innovation by expanding role of Keytruda across new tumor

The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025

Datroway delivers first-ever overall survival breakthrough in 1st-line metastatic triple-negative breast cancer without immunotherapy

Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population